Basiliximab is an intravenous injection used to prevent acute organ rejection immediately following a kidney transplant.
Basiliximab is a targeted biological therapy (monoclonal antibody) used as an immunosuppressant. It is specifically designed as an “induction therapy,” meaning it provides intense, short-term immune suppression at the exact time of transplant surgery to stop the recipient’s body from immediately rejecting the new organ.
Basiliximab is used for people with:
Allogeneic kidney transplantation (preventing acute organ rejection in adults and children receiving a kidney transplant from a donor).
Combination regimens (it is always prescribed alongside a baseline immunosuppressive regimen consisting of a calcineurin inhibitor like ciclosporin, and corticosteroids).
The dose of basiliximab is standardized rather than individualized by weight, provided the patient meets a minimum weight threshold:
Formulation: It is supplied as a powder that is reconstituted and administered exclusively as an intravenous injection or a short intravenous infusion (drip) in a specialist transplant unit.
Standard Adult Regimen: A total dose of 40 mg, given in two separate 20 mg doses. The first 20 mg dose is given within 2 hours prior to the transplant surgery, and the second 20 mg dose is given exactly 4 days after the surgery.
Note: The second dose must not be given if the patient suffers a severe hypersensitivity reaction to the first dose.
Because basiliximab is given in combination with other high-dose post-transplant medications, side effects are common but often related to the overall regimen.
Gastrointestinal symptoms (constipation, nausea, diarrhoea, and abdominal pain).
Metabolic and blood changes (high blood pressure, elevated blood cholesterol, high blood sugar, and low potassium levels).
Peripheral oedema (swelling of the ankles, feet, or lower legs).
Increased vulnerability to serious viral, bacterial, or fungal infections due to suppressed immunity.
Serious but rare allergic reactions (anaphylaxis, severe rash, or breathing difficulties) during or immediately after the injection.
As a monoclonal antibody, basiliximab specifically targets and binds to the alpha-chain of the interleukin-2 receptor (also known as CD25) on the surface of T-lymphocytes (T-cells).
Interleukin-2 is a key chemical messenger that instructs T-cells to multiply and mount an immune attack against foreign tissues.
By blocking this receptor, basiliximab completely prevents T-cell proliferation, temporarily blocking the specific arm of the immune system responsible for attacking and rejecting the donor kidney.
Your transplant clinical team should monitor:
Hypersensitivity reactions closely during and for several hours following the administration of both doses.
Complete blood counts and blood chemistry panels (including renal function and electrolytes) daily in the immediate post-operative period.
Vital signs (blood pressure, heart rate, and temperature) and fluid balance checks continuously.
Signs and symptoms of local or systemic infections, as well as the healing of the surgical wound.
What are the 10 Most Common Water Tablets (Diuretics)? If you are dealing with fluid retention or high blood pressure, your doctor may prescribe diuretics, commonly known as water tablets. These medic...
Roxadustat – an EPO-like tablet for anaemia in CKD patients Roxadustat is an EPO-stimulating tablet for kidney-related anaemia A hormone (erythropoietin, EPO) is normally made by the kidneys. EP...
Common Questions and Answers about Cetirizine Here are 5 common FAQs about cetirizine. 1.❓What is cetirizine used for Cetirizine is an antihistamine used to relieve allergy symptoms such as sne...
Common Questions and Answers about Clopidogrel Here are 5 common FAQs about clopidogrel. 1.❓What is clopidogrel used for Clopidogrel is used to help prevent blood clots from forming. It is comm...
